Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Rx-Partners
WARNING LETTER
•Rx-Partners

Rx-Partners – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Rx-Partners after reviewing its numerous websites, determining they offer unapproved new drugs and misbranded drugs for sale to U.S. consumers, violating sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter highlights that products like "Generic Chloromycetin (chloramphenicol)" are unapproved new drugs, lacking FDA approval under section 505(a), and were previously withdrawn from the U.S. market due to serious safety concerns, including fatal blood disorders. Furthermore, the websites market misbranded drugs. These products fail to bear adequate directions for their intended uses, as required by section 502(f)(1) and 21 CFR 201.5, because they are prescription drugs not suitable for self-treatment. This constitutes the introduction of misbranded drugs into interstate commerce. Additionally, Rx-Partners offers prescription drugs, such as chloramphenicol and Levaquin (levofloxacin), without requiring a valid prescription, which misbrands the products under section 503(b)(1) and violates section 301(k) by dispensing them while held for sale. This practice jeopardizes patient safety due to the significant risks associated with these medications. FDA demands immediate cessation of marketing violative drug products and a written response within 10 working days detailing corrective actions to prevent recurrence, warning of potential regulatory actions like seizure or injunction.

Company
Rx-Partners
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas (TJ) Christl (Office Director)
View Company Profile

ID · f208e505-aef5-43bd-a047-102cd57e93d0

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 331(d)21 U.S.C. 331(k)21 U.S.C. 353(b)21.U.S.C. 355(a)21 U.S.C. 321(p)21 U.S.C. 35521 U.S.C. 352(f)(1)21 CFR 201.521 CFR 201.115

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Rx-Partners
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.